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Objectives. The purpose of this study was to assess the efficacy
of 150 mg ofaspirinow Ill mg of alteplase, administered as two
intravenous bolus injections of 50 mg Brach given 30 min apart, and
followed by intraverroirs heparin, to infarct-related coronary
artery potency (Thrombolysis In Myocardial Infarction ITIMII
flow grade 3).
Baekgroond. Previous workers have shown in animals
red
	
the d of an infusion of recombinant tissue-type
activator increases the initial rate of thrombolysis,
resulting in high early Infarct-related coronary artery patency
rates . The logical progression of this Idea is bolus administration.
Methods . Consecutive patients presenting up to 6 h from the
onset of symptoms were recruited for the study . phy was
performed at 60 and 90min after the first bolus and between 19 to
40 h after study entry . Patients were followed up for 1 month .
Results. At 60 min, angiography revealed infarct-related cor-
onary artery patency of TIMI flow grade 3 In 55 (86%) of 64
Accelerated or "front-loaded" regimens of the thrombolytic
agent alteplase (predominantly single-chain recombinant
tissue-type plasminogen activator [rt-PA)) have excited great
clinical interest (1,2). A regimen of 100 mg of alteplase
delivered over 90 min appears to be significantly more
effective in promoting early coronary perfusion, partial or
complete (Thrombolysis in Myocardial Infarction [TIMI]
flow grade 2 or 3) (3), as measured by coronary angiography
at 60 min, than is a standard 3-h infusion regimen (1) . In
addition, the safety profile of the drug is maintained (4) .
The logical extension of accelerated therapy is the admin-
istration of alteplase as an intravenous bolus . In theory,
bolus administration should not only be more effective
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patients (95% confidence interval [01 75% to 93%) and TIMI
low grade 2 or 3 in 50 (91%) of patients (95% Cl 81 % to 97%) .
At 90 min, infarct-related artery patency of TIMI flow grade 3
was achieved in 74 ( %) of 84 patients (95% 079% to 94%) and
TIMI flow grade 2 or 3 in 78 (93%) of 84 patients (95% CI 85%
to 97%) . Two patients (2.4%) had early angiographic reocclusion
whereas 10 (11 .90) had late r ` arction. Bleeding episodes were
mostly minor, and there was no cerebrovascular bleeding . Five
patients (6.0%) died within I month of the acute myocardial
infarction .
Conclusions . In 84 patients with acute myocardial infarction,
administration of 100 mg of double-bolus (2 x 50 mg) alteplase,
aspirin and heparin is associated with remarkably high early
infarct-related coronary artery patency rates (TIMI flow grade 3)
of % and %, respectively, at 60 and 90 min .
(,f Am Coll Cardiol 1994
;23
:6-10)
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than an equidose infusion but also safer because of rapid
clearance of non-clot-bound alteplase (5) . Bolus admin-
istration also facilitates prehospital administration by dis-
pensing with the need for costly and cumbersome infusion
pumps.
We have previously demonstrated that high early patency
rates conventionally considered to be TIMI flow grade 2 or 3
can be achieved with bolus injections of 1) 10 mg of alteplase
followed by 50 mg ; 2) 50 mg followed by 20 mg ; or 3) 50 mg
followed by 50 mg (total dose 100 mg), with the highest 60-
and 90-min patency rates being achieved in the 100-mg group
(6). However, recent evidence has shown that the incidence
of congestive heart failure, recurrent ischemia and reocclu-
sion, as well as infarct size, are significantly greater in
patients with TIMI flow grade 2 at 90 min versus those with
TIMI flow grade 3 (7--9) . The mortality associated with TIMI
flow grade 2 is also higher than that associated with TIMI
flow grade 3 (7) . We thus investigated alteplase (100 mg)
administered as two bolus injections of 50 mg separated by
30 min, with emphasis on the coronary perfusion grade a
judged by TIMI flow grade 3 .
0735-1097194156 .00
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Methods
Patient selection. Consecutive patients admitted to the
coronary care unit of the Regional Medical Cardiology
Centre through the medically staffed mobile coronary care
unit, the accident and emergency department or cardiac
ward between February and August 1990 and November
1991 to September 1992 were enrolled in the study if they
met the following criteria : They were seen and treated within
6 1. of the onset of symptoms, had chest pain :230-min
duration, were between 18 and 75 years of age and had
electrocardiographic (ECG) changes consistent with acute
myocardial infarction (ST segment elevation 31 mm in two
precordial or two i0erior leads) .
Patients were excluded if they had a history of bleeding
diathesis, recent surgery or trauma, significant hypertension
(>180 mm Hg systolic or >110 mm Hg diastolic blood
pressure), any cerebrovascular event, diabetic retinopathy,
active peptic ulceration or any condition precluding angiog-
raphy or thrombolytic therapy . Patients were also excluded
if they were of child-bearing potential, taking warfarin, had
ECG or historical evidence of previous myocardial infarc-
tion in the area currently affected or an ECG showing left
bundle branch block.
The protocol was approved by the Research Ethical
Committee of the Faculty of Medicine of the Queen's
University of Belfast in November 1989 . Written informed
consent was obtained from the patients or their relatives
before administration of thrombolytic therapy .
Administration of alteplase . Treatment was begun where
the patient was first attended by medical staff. All patients
received intravenous diacetylmorphine for pain relief and
were monitored continuously . Two intravenous cannulas
were inserted into opposite forearm veins for drug adminis-
tration and blood sampling, respectively . Five milliliters of
whole blood was collected immediately before treatment
with alteplase and daily thereafter for 2 days for creatine
kinase (CIA) assay. After receiving 150 mg of soluble aspirin
orally, patients received 50 mg of alteplase (Boebringer
Ingelheint Ltd .) as an intravenous bolus delivered for 3 to
5 min through a forearm cannula . Thirty minutes later, a
second 50-mg bolus of alteplase was administered by the
same route . A 5,000-U intravenous bolus of heparin was
given to all patients up to 90 min after the first bolus of
alteplase .
Study end points . The primary end point of the study was
infarct-related coronary artery patency 90 min after the first
bolus injection (angiogram 2) . Secondary end points were
patency at 60 min (angiogram I), at 19 to 48 h (angiogram 3)
and all clinical events occurring up to I month after treat-
ment. Particular attention was paid to bleeding complica-
tions, angiographic reocclusion (defined as TIM[ flow grade
0or I at the time of angiogram 3 [19 to 48 h] in patients with
previous TIM[ flow grade 2 or 3 at the 90-min angiogram),
recurrent ischemia (defined as further chest pain associated
with ST segment changes of ST segment depression or T
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wave changes, or both,
in ,he ipsilateral ECG leads in the
absence of a further increase in CK occurring from the time
of angiogram 3 up to 30 days) and late reinfarction (defined
as chest pain associated with further ST segment elevation in
the ipsilateral ECG leads, with an elevation of CIA level
above twice the upper limit of normal [upper limit of normal
for CK = 145 Ufliterl occurring from the time of akigiogram
3 up to 30 days) .
Angiographic studies were performed in an approved
laboratory using dosimetered equipment . The average total
dose of radiation administered was 2,500 cGy
CM2 .
Coronary
angiography was performed by the Judkins technique, and
coronary blood flow was assessed according to the TIMI
flow grade (3) . Angiograms were reviewed and graded for
statistical analysis by an independent experienced assessor
from another unit who was aware of ECG data but had no
knowledge of patient identity, treatment and outcome . TIMI
flow grade 3 was defined as complete perfusion (i .e ., the
optimal outcome of thrombolytic treatment), TIMI flow
grade 0 as no perfusions, TIMI flow grade I as penetration
without perfusion, and TIMI flow grade 2 as partial perfu-
sion. In all cases, grading was performed with the first
coronary injection. Intracoronary injection of nitrates was
not permitted . If the infarct-related artery was patent (TIMI
flow grade 2 or 3) at 90 min, an intravenous infusion of
heparin was begun at a rate of 1,000 U/h for 5 days . In
addition, one patient with TIMI flow grade 2 patency under-
went mechanical probing by the operator . Patients who did
not obtain reperfusion at 90 min (TIMI flow grade 0 or 1)
underwent mechanical probing of the obstruction, followed
by intravenous heparin at 1,000 Wh for 5 days. Early
reocclusion was assessed by coronary angiography 19 to 48 h
after the first bolus injection .
Statistical considerations . Statistical analysis was per-
formed on an IBM-compatible 486DX personal computer
using SPS51FC+ version 4 .0 software (SPSS Inc .) . Data are
expressed as mean value ± I SD . Percents are followed by
their 95% confidence intervals (95% CI) . The conventional
5% level of statistical significance was adopted as standard .
Results
Study patients . Ninety consecutive patients were treated .
Six patients were excluded from analysis : One patient was
treated >6 h after the onset of symptoms ; in another patient,
it proved impossible to gain arterial access ; a third patient
developed an acute anaphylactoid reaction after the admin-
istration of the first bolus of alteplase, which precluded
angiography ; and three patients, on further survey of the
initial ECG, did not meet inclusion criteria. Thus, 84 patients
(55 men, 29 women ; mean age 58 ± 10 years [range 29 to 74])
were included in the analysis
. There were 49 anterior and 35
inferior infarctions with classic ECG criteria as previously
defined, with CIA levels greater than twice the upper limit of
normal .
Mean delay from onset of symptoms to first bolus injec-
Values presented are mean value t I SD or number of patients .
tion was 153 ± 89 min (range 30 to 360) . Fifty-eight patients
received their first bolus injection outside hospital from the
mobile coronary care unit staff (mean delay 135 ± 79 min,
median 115 min, range 33 to 360) compared with 26 patients
who commenced treatment in hospital (mean delay 193
97 min, median 202.5 min, range 30 to 360) . The difference in
the mean time delay between the two groups was statistically
significant (p < 0.05) but did not yield any statistically
significant difference in patency rates or size of infarct as
measured by peak serum CK (defined as the highest CK
level recorded during days I and 2 of hospital admission) .
The baseline characteristics of the study patients are listed in
Table 1 .
Angiographic data. Coronary angiography was per-
formed in 64 patients (76%) 60 min after the first bolus
injection (angiogram 1). The TIMI flow grades obtained are
listed in Table 2. A favorable outcome (TIMI flow grade 3)
was observed in 55 (86%) of 64 patients (95% CI 75% to 93%)
(Fig . 1) . Conventional infarct-related coronary artery pa-
tency (TIMI flow grade 2 or 3) was observed in 58 (91%) of
64 patients (95% CI 81% to 97%). Residual thrombus was
identified in a patent artery (TIMI flow grade 3) in five
patients . All 84 patients were studied at 90 min (angiogram 2,
Table 2) . The infarct-related artery was the left anterior
descending coronary artery in 40 patients, the left circumflex
coronary artery in 9 and right coronary artery in 35 . A TIMI
flow grade 3 patency was obtained in 74 (88%) of 84 patients
(95% Cl 79% to 94%) . A TIMI flow grade 2 or 3 patency was
obtained in 78 (93%) of 84 patients (95% CI 85% to 97%) .
Those patients with TIMI flow grade 2 or 3 at 60 min
maintained the Same grade at the 90-min angiogram . There
was no statistically significant difference between the TIMI
Table 2
. Thrombolysis in Myocardial Infarction Trial Flow Grade
at the Three Angiographic End Points
*Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 at the time of
angiogram 2
. tTMMI flow grade 0 to 2 at the time of angiogram 2
.
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flow grade 3 patency rates at 60 and 90 min (86% vs . 88%) .
Residual thrombus was identified in a patent artery (TIMI
flow grade 3) in eight patients at 90 min . Sixty-nine of 74
patients with TIMI flow grade 3 at 90 min returned for
follow-up angiography (angiogram 3) between 19 and 48 h
(mean delay 32 h) after the first bolus . Sixty-six (96%) of 69
patients (95% CI 88% to 99%) had retained TIMI flow grade
3 patency. One patient exhibited TIMI flow grade 2 patency
at this end point, and two patients exhibited angiographic
reocclusion (TIMI flow grade 0 or 1) (Table 2) . Five of 74
patients did not return for angiography : One died of cardio-
genic shock .; another died of myocardial rupture, and three
were deemed too ill to undergo repeat cardiac catheteriza-
tion . Nine of the 10 patients who had TIMI flow grade 0 to 2
at 90 min (and had mechanical probing at that time) returned
for repeat angiography, and 6 achieved TIMI flow grade 3 at
angiogram 3 (Table 2) . One of the 10 patients did not return
for angiography because of development of a ventricular
septal defect . This patient did not survive cardiopulmonary
bypass after operative repair . Figure 1 illustrates the percent
of patients achieving TIM[ flow grade 2 or 3 patency at the
angiographic end points .
Ten patients (11 .9%) with TIM[ flow grade 3 patency at
90 min experienced late reinfarction . Eight of these 10 had
angiography at both 60 and 90 min . In these eight there was
no instance of delayed reperfusion (i .e ., occlusion at 60 min
but patency at 90 min) . Two of these patients had residual
thrombus identified in the infarct-related artery during either
angiogram I or angiogram 2 . Eight patients (9 .5%) had
recurrent ischemia .
Twenty-five patients (30%) underwent revascularization
procedures within 30 days of study entry : elective percuta-
neous transluminal coronary angioplasty in 18, directional
coronary atherectomy in 2 and coronary artery bypass
grafting in 5 . One elective angioplasty proved unsuccessful
and required emergency coronary artery bypass grafting . In
all 20 patients who underwent elective angioplasty or
atherectomy, the procedure was performed because of high
grade (>90%) residual stenosis : The stenosis alone was the
reason for the procedure in 10 patients ; 5 others mad asso-
ciated recurrent ischemia and 5 had late reinfarction . Three
of the five patients who underwent coronary artery bypass
grafting had recurrent ischemia, and two had late reinfarc-
tion.
Adverse events . In general, bleeding complications were
minor. There were no cerebrovascular bleeding episodes .
The most common bleeding complication was bruising or
hematoma formation at the arterial puncture site . Five
patients required a blood transfusion . Arrhythmic events
were infrequent . Three patients had ventricular fibrillation
before thrombolytic therapy . One patient had ventricular
fibrillation 10 min after receiving the first bolus injection
(TIMI flow grade 3 patency at 60 min), whereas another had
ventricular fibrillation 35 min after the second bolus injec-
tion. Another patient with intractable heart failure had
ventricular fibrillation on day 15 and died on day 16 . Two
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Table 1 . Baseline Characteristics of the 84 Patients in the
Study Group
Age (yr) 58
± 10
Male/female
55129
Weight (kg)
7,- ± 12
Weight-related dosage (mg/kg body wt) 1 .39 ± 0.23
Initial heart rate (beats/min) 72 ± 12
Initial blood pressure (mm Hg) 128/76 ± 1618
Delay from symptom onset to first bolus (min) 153 ± 89
0 4 5 I 2
I 2 1 I 1
2 3 4 I 0
3 55 74 66 6
TIMI
Flow
Grade
Angiogram I
(n = 64)
Angiogram 2
(n = 84)
Angiogram 3
a = 69* n = 9t
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Figure 1 . Comparison of infarct-related artery pa-
tency rates ( 17c Thrombolysis in Myocardial Infarc-
lion LTIMII How grade 2 or 3) at the three angio-
graphic end points . *TIMI flow grade 3 at angiogram
(Angio) 2 . 'T1111 flow grade 0 to 2 at angiogram 2 .
20
patients required intravenous antiarrhythmic therapy for
sustained ventricular tachycardia . Two patients presented in
complete heart block with hypotension but returned to 1 ;1
atrioventricular conduction with normal blood pressure 35
and 50 min, respectively, after the first bolus . No patient
required temporary ventricular pacing .
One patient had an anaphylactoid reaction resembling
angioedema shortly after the administration of the first bolus
of alteplase . The patient tested negative for anti-tissue
plasminogen activator antibodies .
Five (6%) of 84 patients died during the course of the
study . Two of these patients exhibited TIMI flow grade 3
patency at 90 min but subsequently died, one of myocardial
rupture at 3 h and one of cardiogenic shock at 12 h from
study entry . The remaining three patients died of cardiogenic
shock on day 2, ventricular septa) defect on day 2 and
intractable left ventricular failure on day 16 .
Discussion
Rationale for bolus ad minioration. New approaches to
the administration of thrombolytic therapy must be associ-
ated with higher patency rates than those achieved with
routine thrombolytic regimens while maintaining a good
safety profile with no excess of reocclusion . Current evi-
dence suggests that the most satisfactory outcome of throm-
bolytic therapy in terms of infarct size and mortality is early
sustained TIMI flow grade 3 patency (7-10) . To succeed,
therefore, a new regimen must produce a high proportion of
TIMI flow grade 3 patency in infarct-related vessels at all
stages .
Original laboratory work with rt-PA has demonstrated
that decreasing the duration of administration of a given dose
produces a greater initial rate of thrombolysis, whereas the
final extent of clot dissolution is constant (11,12) . These
findings have been borne out by the randomized angio-
PURVIS ET AL .
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Angio 1 Angio 2 Angio 3 Angic 3
J%gwgram
__~ TW grade 3 1- TIMI grade 2
graphic trial of rt-PA (alteplase) in myocardial infarction
study (4), which demonstrated a significantly higher 60-min
infarct-related coronary artery patency rate (TIMI flow
grade 2 or 3) with an accelerated 90-min infusion of alteplase
compared with results of a standard 3-h infusion (76% vs .
63%, respectively, p = 0,03), At 90 min there was no
significant difference in patency rates between the two
groups (4),
it would seem logical to extend the concept of accelerated
dosing to the administration of bolus alteplase . Unfortu-
nately, clinical trials utilizing a single bolt's dose of alteplase
have proved disappointing in acute myocardial infarction
(13,14), although single-bolus alteplase therapy does seem
useful in pulmonary embolism (15) . Duteplase (predomi-
nantly double-chain rt-PA) and long half-life variants of
rt-PA have shown some promise when administered in acute
myocardial infarction as a single intravenous bolus (16-18) .
A more exciting approach is double-bolus alteplase therapy,
with reported perfusion rates (TIMI flow grade 2 or 3) of
approximately 80% at 90 min for total doses of 70 and 100 mg
of alteplase (6,19) .
Angiographic analysis of efficacy . Our results show that at
60 min, with a regimen of 100 mg of double-bolus alteplase,
86% of patients exhibit TIMI flow grade 3 patency, and TIMI
flow grade 2 or 3 can be achieved in 91% of patients . These
results would be considered excellent even at the 90-min end
point and confirm that the bolus administration of alteplase
greatly increases the initial rate of thrombolysis . Compari-
son of these results with the 60-min patency results achieved
previously with an accelerated 100-mg infusion (4) suggests a
significant improvement with bolus therapy over accelerated
infusion therapy for both TIMI flow grade 3 patency rates
(chi-square = 10 .46, degrees of freedom LldQ = 1, p = 0
.012)
and TIMI flow grade 2 or 3 patency rates (chi-square = 5 .47,
df = 1,p=0 .019) .
In this study at 90 min, TIM] flow grade 3 patency was
10
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recorded in 88% of patients, and TIMI flow grade 2 or 3
patency in 93% of patients . These results are nearly identical
to those recorded at 60 min and imply that with the double-
bolus regimen, early and relatively complete thrombolysis is
achieved before the 60-min end point . Comparison of the
90-min patency rates with previous study data (4) also
suggests a significant improvement over accelerated infusion
therapy for both TIMI flow grade 3 patency rates (chi-square
= 17.86, df = I, p = 0.00003) and TIMI flow grade 2 or 3
patency (chi-square = 5 .62, df = 1, p = 0.018).
There were 2 angiograpaiiti .`u~Liusiun~ (2 .4%) and HUI
late reinfarctions (11 .9%) during follow-up. The total inci-
dence of presumed vessel closure is thus 14 .3%. This rate is
similar to the 9 .4% and at least 15% quoted in other
published studies with accelerated alteplase therapy (1,4) .
Heparin was not administered in this study before the
second bolus of alteplase was given, and earlier administra-
tion may have reduced the incidence of reocclusion . It
seems, however, that the original concern that the short
plasma half-life of rt-PA would lead to excessive reocclusion
is unfounded (20).
Adverse events . In keeping with Agnelli's experimental
observations (5), bleeding complications were minor and
mostly related to angiography or preexisting disease . There
was no cerebrovascular bleeding . One patient had an ana-
phylactoid reaction after receiving the first bolus of alteplase
(21) . This unusual phenomenon has also been reported with
an infusion regimen of alteplase (22) . The mortality rate of
6.0% in this study is comparable to that of large mortality
studies with alteplase (23) .
Ctmchrslons . This pilot study was designed to investigate
the angiograpllic efficacy of the 100-mg double-bolus regi-
men. The limited safety data obtained seem encouraging, in
keeping with data from other bolus regimen studies (6,13-
19,24). The administration of 100 mg of double-bolus al-
teplase in acute myocardial infarction results in remarkably
high early TIMI flow grade 3 infarct-related coronary artery
patency rates (86% and % at 60 and 90 min, respectively) .
A TIM[ flow grade 2 or 3 patency was achieved in 91% and
93% of patients at 60 and '90 min, respectively ; the rates
compare very favorably with those of accelerated infusion
therapy. A direct, randomized, controlled comparison with
accelerated infusion therapy is now under way, and we may
see this exciting new regimen achieve its full potential .
We thank Dr
. [an Hutton, Consultant Cardiologist, Glasgow Royal Infirmary,
for interpreting and grading the angiograms
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